Abstract
We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.
| Original language | English |
|---|---|
| Pages (from-to) | 341-342 |
| Number of pages | 2 |
| Journal | Psychiatry and Clinical Neurosciences |
| Volume | 50 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jan 1 1996 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia : A preliminary report. / Yamada, Kazuo; Kanba, Shigenobu; Murata, Takaaki; Fukuzawa, Motoko; Terashi, Bokusou; Yagi, Gohei; Asai, Masahiro.
In: Psychiatry and Clinical Neurosciences, Vol. 50, No. 6, 01.01.1996, p. 341-342.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness of Shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia
T2 - A preliminary report
AU - Yamada, Kazuo
AU - Kanba, Shigenobu
AU - Murata, Takaaki
AU - Fukuzawa, Motoko
AU - Terashi, Bokusou
AU - Yagi, Gohei
AU - Asai, Masahiro
PY - 1996/1/1
Y1 - 1996/1/1
N2 - We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.
AB - We investigated the efficacy of Shakuyaku-kanzo-to (TJ-68) in neuroleptic-induced hyperprolactinemia in 11 treated schizophrenic patients. The mean plasma prolactin level decreased significantly from 28.9 ± 14.5 ng/mL at baseline to 22.0 ± 15.2 ng/mL at 4 weeks. Potassium levels did not change significantly. Neither the exacerbation of psychosis nor other adverse effects occurred.
UR - http://www.scopus.com/inward/record.url?scp=0030459961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030459961&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1819.1996.tb00578.x
DO - 10.1111/j.1440-1819.1996.tb00578.x
M3 - Article
C2 - 9014235
AN - SCOPUS:0030459961
VL - 50
SP - 341
EP - 342
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 6
ER -